Back to Search
Start Over
Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia.
- Source :
- Acta Haematologica; Oct2009, Vol. 122 Issue 1, p6-10, 5p, 1 Chart
- Publication Year :
- 2009
-
Abstract
- The article describes the clinical outcome of 11 patients, particularly nine patients with chronic myeloid leukemia (CML) and two patients with Philadelphia-positive acute lymphoblastic leukemia (Phi+ ALL), who received second-generation tyrosine kinase inhibitor (TKI) treatment in the post-transplant period. The preliminary findings show that application of second generation tyrosine kinase inhibitors is feasible in the post-transplant period. The researchers note that tolerance might be comparable with the application in a standard treatment scenario.
Details
- Language :
- English
- ISSN :
- 00015792
- Volume :
- 122
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Acta Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 44713798
- Full Text :
- https://doi.org/10.1159/000228587